Lensar (LNSR) Net Cash Flow Growth (3y) (2022 - 2026)
Lensar (LNSR) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.75 Bn | 176.46 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 129.05 Bn | 126.17 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 108.57 Bn | 99.35 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 68.61 Bn | 67.16 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 48.41 Bn | 44.74 Bn | 1.29 Bn | -87.88% |
| 6 | Dexcom | 28.35 Bn | 27.23 Bn | 750.30 Mn | 129.29% |
| 7 | GE HealthCare Technologies | 28.12 Bn | 25.83 Bn | 1.98 Bn | -65.12% |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 24.26 Bn | 21.14 Bn | 2.07 Bn | -48.90% |
| 10 | Lensar | 65.97 Mn | 54.88 Mn | 6.38 Mn | 58.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.48% |
| Dec 31, 2025 | 46.67% |
| Sep 30, 2025 | 27.70% |
| Jun 30, 2025 | -64.20% |
| Mar 31, 2025 | 47.94% |
| Dec 31, 2024 | 117.35% |
| Sep 30, 2024 | 43.80% |
| Jun 30, 2024 | -56.41% |
| Mar 31, 2024 | -12.08% |
| Dec 31, 2023 | -26.93% |
| Sep 30, 2023 | -26.29% |
| Jun 30, 2023 | -45.34% |
| Mar 31, 2023 | -47.88% |
| Dec 31, 2022 | -50.02% |